The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | A real-world analysis of belantamab mafodotin in patients with R/R multiple myeloma
In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, briefly summarizes a real-world analysis which investigated the safety and efficacy of belantamab mafodotin in the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Landgren highlights some of the findings from this study, including safety information, response rates of patients, and ocular adverse events, and the importance of conducting real-world analyses on newly approved drugs. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
